ChromaDex (CDXC) Trading Down 8.2%

ChromaDex Corporation (NASDAQ:CDXC) was down 8.2% on Tuesday . The stock traded as low as $6.00 and last traded at $6.06. Approximately 556,031 shares were traded during trading, an increase of 77% from the average daily volume of 313,354 shares. The stock had previously closed at $6.60.

Several equities research analysts recently weighed in on CDXC shares. HC Wainwright set a $5.00 price objective on shares of ChromaDex and gave the stock a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research raised shares of ChromaDex from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research report on Tuesday, November 28th. Ladenburg Thalmann Financial Services started coverage on shares of ChromaDex in a research report on Monday, September 25th. They set a “buy” rating and a $7.00 price objective for the company. Finally, ValuEngine raised shares of ChromaDex from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $7.13.

The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 4.12.

In related news, major shareholder River Ventures Ltd Champion bought 731,707 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was purchased at an average price of $4.10 per share, with a total value of $2,999,998.70. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.59% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Thompson Davis & CO. Inc. bought a new position in shares of ChromaDex in the third quarter worth about $128,000. Bank of Montreal Can bought a new position in shares of ChromaDex in the second quarter worth about $168,000. LMR Partners LLP bought a new position in shares of ChromaDex in the second quarter worth about $347,000. Goldman Sachs Group Inc. lifted its holdings in shares of ChromaDex by 870.6% in the second quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after acquiring an additional 163,817 shares during the last quarter. Finally, Granite Investment Partners LLC lifted its holdings in shares of ChromaDex by 5.7% in the third quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after acquiring an additional 13,599 shares during the last quarter. 6.82% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “ChromaDex (CDXC) Trading Down 8.2%” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/12/06/chromadex-cdxc-trading-down-8-2.html.

ChromaDex Company Profile

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Receive News & Ratings for ChromaDex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply